Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.5%

1 terminated out of 22 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

41%

9 trials in Phase 3/4

Results Transparency

13%

2 of 15 completed with results

Key Signals

2 with results94% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (2)
P 1 (2)
P 2 (1)
P 3 (1)
P 4 (8)

Trial Status

Completed15
Recruiting3
Unknown2
Not Yet Recruiting1
Terminated1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT02190253CompletedPrimary

Seroprevalence of Hepatitis E in People With an Organ Transplant

NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT06859619Not ApplicableNot Yet Recruiting

Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases

NCT06564116Phase 4CompletedPrimary

Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above

NCT06457438Not ApplicableRecruitingPrimary

Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors

NCT06137313RecruitingPrimary

Exposure to Hepatitis E Virus in Occitania, France

NCT05976594UnknownPrimary

Long-term Effectiveness of a Recombinant Hepatitis E Vaccine

NCT03827395Phase 1CompletedPrimary

Safety Study of Hepatitis E Vaccine (HEV239)

NCT04670419CompletedPrimary

Morbidity and Mortality of Hepatitis E Virus Infections in Belgium

NCT01014845Phase 3CompletedPrimary

Clinical Trial of Recombinant Hepatitis E Vaccine

NCT03365921Phase 4CompletedPrimary

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)

NCT03601221CompletedPrimary

Seroprevalence Hepatitis E Infection in Healthy Blood Donors

NCT02964910Phase 4CompletedPrimary

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

NCT02558114Phase 4TerminatedPrimary

Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.

NCT03282474Phase 2CompletedPrimary

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

NCT03168412Phase 4CompletedPrimary

A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)

NCT02189603Phase 4CompletedPrimary

Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®)

NCT03488589UnknownPrimary

HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver

NCT02847507Completed

Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)

NCT02584543Phase 4CompletedPrimary

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)

Scroll to load more

Research Network

Activity Timeline